AstraZeneca has set itself a challenging new target to nearly double its revenues to $80bn and launch 20 new medicines by 2030.
The company earned $45.8bn in 2023 and believes it can sustain one of the best growth rates in the sector to reach its new target in six years’ time
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?